880880-53-5

Upstream product

• 624-67-9 Propargylic aldehyde 
• 104-94-9 4-methoxy-aniline 

Downstream Products

• 105620-52-8 dl 3,4-trans-1-(p-methoxyphenyl)-3-acetyl-4-ethylyl-2-azetidinone 
• 123537-15-5 (3S,4S)-3-Acetyl-4-ethynyl-1-(4-methoxy-phenyl)-azetidin-2-one 
• 105662-83-7 (3R,4S)-4-Ethynyl-3-((S)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 
• 105662-82-6 (3R,4S)-4-Ethynyl-3-((R)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 
• 123537-14-4 (3S,4S)-4-Ethynyl-3-((S)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 
• 105662-84-8 (3S,4S)-4-Ethynyl-3-((R)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 
• 105620-48-2 (3R,4R)-4-Ethynyl-3-((S)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 
• 109279-02-9 (3R,4R)-4-Ethynyl-3-((R)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 
• 105662-85-9 (3S,4R)-4-Ethynyl-3-((S)-1-hydroxy-ethyl)-1-(4-methoxy-phenyl)-azetidin-2-one 

Relevant academic research and scientific papers

Stereoselective synthesis of fused bicyclic β-lactams through radical cyclization of enyne-2-azetidinones

A convenient, stereoselective entry to racemic and enantiomerically pure fused bicyclic β-lactams has been developed that involves the radical- mediated cycloisomerization of easily available monocyclic enyne-β-lactams as the key synthetic step. These compounds are obtained provided that an activated double bond is present as a radical acceptor. In the absence of this condition, new forms of reactivity were observed, including C3-C4 bond cleavage of the β-lactam ring to yield tetrahydropyridine derivatives and 1,5-radical translocation to yield new bicyclic derivatives. Some simple transformations were tested on representative examples of the different types of bicyclic systems prepared to demonstrate their potential as intermediates in the preparation of other differently functionalized systems.

PROTEASOME INHIBITING ?-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS

The present invention relates generally to proteasome inhibiting β-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formulations of said compounds, and medical uses of said compounds and/or pharmaceutical compositions to treat cancer and neurodegenerative disorders.